$5.47
0.55%
NYSE, Oct 08, 04:00 pm EDT. Closed.
ISIN
US05588W1080
Symbol
LEO

BNY Mellon Strategic Municipals Inc Stock price

$5.47
-0.57 9.44% 1M
-0.97 15.06% 6M
-0.89 13.99% YTD
-0.81 12.90% 1Y
+0.14 2.63% 3Y
-3.06 35.87% 5Y
-3.26 37.34% 10Y
-3.65 40.02% 20Y
NYSE, Closing price Thu, Oct 08 2026
+0.03 0.55%
ISIN
US05588W1080
Symbol
LEO

Is BNY Mellon Strategic Municipals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
$328.9m
Enterprise Value
$546.8m
Net debt
$217.9m
Cash
$90.0k
Shares outstanding
62.0m
Valuation
P/E
27.2
P/S | estimate
11.0 | -
EV/Sales | estimate
18.2 | -
EV/FCF | ex SBC
21.1 | -
P/B
0.8
Dividends
DPS
$0.27
Yield 1Y | 5Y
5.0% | 4.6%
Growth 1Y | 5Y
20.2% | -8.2%
Payout 1Y | 3Y
-108.6% | 79.7%
Increased
1 Year
Financials
Revenue | estimate
$30.0m | -
EBITDA
-
EBIT
$19.1m
Net Income
$12.7m
Free Cash Flow | ex SBC
$25.9m | -
Growth
Revenue | estimate
3.5% | -
EBITDA
-
EBIT
11.7%
Net Income
533.0%
Free Cash Flow
213.1%
Margin
Gross
75.8%
EBITDA
-
EBIT
63.8%
Net
42.2%
Free Cash Flow | ex SBC
86.5% | -
Financial Health
Equity Ratio
65.5%
Return on Equity
-3.1%
ROCE
3.0%
ROIC
-
Debt/Equity
0.5
More
EPS
$0.2
FCF per Share
$0.4
Short interest
0.2%
Employees
-
Rev per Employee
-

Financial data from BNY Mellon Strategic Municipals Inc

Mar '26
+/-
%
30 30
3% 3%
100%
- Direct Costs 7.26 7.26
15% 15%
24%
23 23
11% 11%
76%
- Selling and Administrative Expenses 4.19 4.19
1% 1%
14%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 19 19
12% 12%
64%
Net Profit 13 13
533% 533%
42%

In millions USD.

Don't miss a Thing! We will send you all news about BNY Mellon Strategic Municipals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BNY Mellon Strategic Municipals Inc Stock News

Neutral
Business Wire
●
8 days ago
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma presents new tralokinumab data at EADV 2026.
Neutral
Business Wire
●
21 days ago
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces FDA acceptance of dersimelagon NDA with Priority Review and closes acquisition from Tanabe Pharma.
Positive
Reuters
●
about 2 months ago
Danish drugmaker LEO Pharma said on Tuesday it had agreed to acquire worldwide rights ​to drug candidate dersimelagon from Tanabe Pharma for ‌up to $435 million in up-front and near-term milestone payments.

Company Profile

BNY Mellon Strategic Municipals, Inc. is a closed-end investment fund and investment trust. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The company was founded in 1987 and is headquartered in New York, NY.

Head office United States
Founded 1987
Website www.bny.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today